⚠️

Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.

Read our methodology →

Irfan JawedMD

Hematology-Oncology · Houston, TX 77089

NPI: 1356508501

Share:

38

🟠 Elevated

Risk Flags

Extreme opioid rate vs specialty peers95th percentile opioid prescribingElevated cost per beneficiary

Risk indicators are statistical patterns, not allegations. Learn more

1,635

Total Claims

$1.3M

Drug Cost

188

Beneficiaries

$7,121

Cost/Patient

Risk Score Breakdown 38/100

Low (0)Moderate (15)Elevated (30)High (50+)
Opioid rate vs specialty peers+25
Opioid rate (national percentile)+10
Cost per patient outlier+3

Score components are additive. Read full methodology

Peer Comparison vs. 8,541 Hematology-Oncology providers

+674%

Opioid rate vs peers

48.6% vs 6.3% avg

-48%

Cost per patient vs peers

$7,121 vs $14K avg

-18%

Brand preference vs peers

11.9% vs 14.6% avg

⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.

🔎 Data Overview

⚠️

Opioid prescribing rate is 674% above the average for Hematology-Oncology providers. While some providers legitimately treat pain-heavy populations, deviations of this magnitude are rare and warrant examination.

Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.

Opioid Prescribing

48.6%

Opioid Rate

794

Opioid Claims

$16K

Opioid Cost

12.0%

Long-Acting Rate

This provider's opioid prescribing rate of 48.6% is above the 20% threshold that CMS considers elevated.

Brand vs Generic

88% generic

Brand: 195 claims · $1.3M

Generic: 1,440 claims · $79K

Patient Profile

68

Avg Age

64%

Female

3.51

Avg Risk Score

Explore More

Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About